Previous 10 | Next 10 |
Shares of Legend Biotech Corporation (NASDAQ:LEGN) traded at a new 52-week high today of $52.57. Approximately 149,000 shares have changed hands today, as compared to an average 30-day volume of 374,000 shares. Legend Biotech Corporation (NASDAQ:LEGN) has potential upside of 10.6% based ...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Legend Biotech Corporation (NASDAQ:LEGN) traded today at a new 52-week high of $52.02. This new high was reached on below average trading volume as 149,000 shares traded hands, while the average 30-day volume is approximately 362,000 shares. Potential upside of 11.5% exists for Legend Bi...
Shares of Legend Biotech Corporation (NASDAQ:LEGN) traded at a new 52-week high today of $51.23. So far today approximately 149,000 shares have been exchanged, as compared to an average 30-day volume of 381,000 shares. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It...
Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will host its first Research & Development Day on Monday, October 18, commencing at 10:00...
Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Suzhou Sinovent and SinoMab Bio in a $561 million deal. The company also announced a $500 million two-part deal with Providence Therapeutics of Calvery, Canada for mRNA products. Cue Health, a San Diego...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced the start of a Phase 1 clinical trial in the United States for...
The following slide deck was published by Legend Biotech Corporation in conjunction with this event. For further details see: Legend Biotech Corporation (LEGN) Investor Presentations - Slideshow
Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the 19 th Annual Morgan Stanley Virtual Global Healthcare Conference ...
Investigational BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel) granted priority review by the U.S. Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma (RRMM) A Marketing Authorisation Application (MAA) was accepted by the Europ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...